ABSTRACT
We investigated the risk factors for pulmonary hypertension (PH) in patients receiving maintenance peritoneal dialysis (MPD). A group of 180 end-stage renal disease patients (124 men and 56 women; mean age: 56.43±8.36) were enrolled in our study, which was conducted between January 2009 and June 2014. All of the patients received MPD treatment in the Dialysis Center of the Second Affiliated Hospital of Soochow University. Clinical data, laboratory indices, and echocardiographic data from these patients were collected, and follow-ups were scheduled bi-monthly. The incidence and relevant risk factors of PH were analyzed. The differences in measurement data were compared by t-test and enumeration data were compared with the χ2 test. Among the 180 patients receiving MPD, 60 were diagnosed with PH. The remaining 120 were regarded as the non-PH group. Significant differences were observed in the clinical data, laboratory indices, and echocardiographic data between the PH and non-PH patients (all P<0.05). Furthermore, hypertensive nephropathy patients on MPD showed a significantly higher incidence of PH compared with non-hypertensive nephropathy patients (P<0.05). Logistic regression analysis showed that the proportion of internal arteriovenous fistula, C-reactive protein levels, and ejection fraction were the highest risk factors for PH in patients receiving MPD. Our study shows that there is a high incidence of PH in patients receiving MPD and hypertensive nephropathy patients have an increased susceptibility to PH.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Arteriovenous Fistula/complications , Hypertension, Pulmonary/etiology , Peritoneal Dialysis/adverse effects , C-Reactive Protein/analysis , China/epidemiology , Hypertension, Pulmonary/epidemiology , Incidence , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Natriuretic Peptide, Brain/blood , Phosphorus/blood , Prospective Studies , Risk FactorsABSTRACT
Dilated cardiomyopathy (DCM) is characterized by ventricular dilatation, and it is a common cause of heart failure and cardiac transplantation. This study aimed to explore potential DCM-related genes and their underlying regulatory mechanism using methods of bioinformatics. The gene expression profiles of GSE3586 were downloaded from Gene Expression Omnibus database, including 15 normal samples and 13 DCM samples. The differentially expressed genes (DEGs) were identified between normal and DCM samples using Limma package in R language. Pathway enrichment analysis of DEGs was then performed. Meanwhile, the potential transcription factors (TFs) and microRNAs (miRNAs) of these DEGs were predicted based on their binding sequences. In addition, DEGs were mapped to the cMap database to find the potential small molecule drugs. A total of 4777 genes were identified as DEGs by comparing gene expression profiles between DCM and control samples. DEGs were significantly enriched in 26 pathways, such as lymphocyte TarBase pathway and androgen receptor signaling pathway. Furthermore, potential TFs (SP1, LEF1, and NFAT) were identified, as well as potential miRNAs (miR-9, miR-200 family, and miR-30 family). Additionally, small molecules like isoflupredone and trihexyphenidyl were found to be potential therapeutic drugs for DCM. The identified DEGs (PRSS12 and FOXG1), potential TFs, as well as potential miRNAs, might be involved in DCM.
Subject(s)
Humans , Cardiomyopathy, Dilated/genetics , Computational Biology/methods , Gene Expression Profiling/methods , Transcriptome , Reference Values , Transcription Factors/genetics , Signal Transduction/genetics , Receptors, Androgen/genetics , Down-Regulation , Up-Regulation , MicroRNAsABSTRACT
En 19 lactantes marasmaticos, con un deficit porcentual de 25,15 +/ 12,83% para la talla actual, en fase de estabilizacion y con una dieta calorica-proteica adecuada, se comprobo excrecion urinaria normal de zinc y manganeso y, aparentemente, un incremento en la excrecion de cobre